Scientech Research LLC Has $1.37 Million Stock Holdings in Bruker Corporation $BRKR

Key Points

• Scientech Research LLC has increased its stake in Bruker Corporation by 62.8% during the 1st quarter, now holding 32,728 shares valued at approximately $1.37 million.
• Bruker reported a net margin of 2.31% and quarterly earnings per share of $0.32, which fell short of analysts' expectations of $0.33.
• The company has declared a $0.05 dividend to be paid on October 3rd, with a current payout ratio of 38.46%.

Scientech Research LLC raised its stake in Bruker Corporation (NASDAQ:BRKR - Free Report) by 62.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 32,728 shares of the medical research company's stock after acquiring an additional 12,621 shares during the quarter. Scientech Research LLC's holdings in Bruker were worth $1,366,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the company. Comerica Bank increased its stake in shares of Bruker by 2.0% during the fourth quarter. Comerica Bank now owns 36,866 shares of the medical research company's stock worth $2,161,000 after purchasing an additional 734 shares during the period. Mercer Global Advisors Inc. ADV bought a new position in Bruker during the 4th quarter worth $249,000. BNP Paribas Financial Markets increased its position in Bruker by 257.3% during the 4th quarter. BNP Paribas Financial Markets now owns 84,758 shares of the medical research company's stock worth $4,969,000 after buying an additional 61,036 shares during the period. Captrust Financial Advisors lifted its holdings in shares of Bruker by 32.7% during the fourth quarter. Captrust Financial Advisors now owns 5,973 shares of the medical research company's stock worth $350,000 after buying an additional 1,472 shares in the last quarter. Finally, Cetera Investment Advisers boosted its position in shares of Bruker by 13.8% in the fourth quarter. Cetera Investment Advisers now owns 23,083 shares of the medical research company's stock valued at $1,353,000 after acquiring an additional 2,799 shares during the period. Institutional investors own 79.52% of the company's stock.

Analyst Upgrades and Downgrades

BRKR has been the topic of a number of recent research reports. Bank of America lowered their price target on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. Stifel Nicolaus set a $40.00 target price on shares of Bruker and gave the stock a "hold" rating in a report on Tuesday, August 5th. Jefferies Financial Group set a $60.00 price target on shares of Bruker and gave the company a "buy" rating in a research report on Monday, August 4th. Citigroup reduced their price target on Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a research report on Monday, August 4th. Finally, Barclays dropped their price objective on Bruker from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Monday, August 4th. Five research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Bruker presently has an average rating of "Hold" and a consensus price target of $51.30.

Bruker Price Performance

NASDAQ:BRKR traded down $0.28 during mid-day trading on Friday, reaching $31.80. The stock had a trading volume of 1,379,996 shares, compared to its average volume of 2,666,476. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $72.94. The stock has a market capitalization of $4.82 billion, a PE ratio of 61.14, a P/E/G ratio of 4.23 and a beta of 1.21. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. The stock has a 50-day simple moving average of $36.25 and a two-hundred day simple moving average of $39.11.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $797.40 million during the quarter, compared to analyst estimates of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company's revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, equities analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be given a $0.05 dividend. The ex-dividend date is Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.6%. Bruker's dividend payout ratio (DPR) is currently 38.46%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.